Lv4
690 积分 2021-09-22 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
49分钟前
待确认
Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
5天前
已完结
MUC16 as a novel therapeutic target for high-grade endometrial cancer
12天前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
15天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
18天前
已完结
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
21天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
25天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
25天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
25天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
25天前
已完结
皖公网安备34019202002308
